| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8780923 | Gynecologic Oncology Reports | 2018 | 4 Pages |
Abstract
Sacituzumab govitecan may present a new treatment option for recurrent USC patients harboring Trop-2+ tumors resistant to chemotherapy. Clinical trials with sacituzumab govitecan are warranted.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Chanhee Han, Stefania Bellone, Peter E. Schwartz, Serengulam V. Govindan, Robert M. Sharkey, David M. Goldenberg, Alessandro D. Santin,